

ASTRO's 66th Annual Meeting

Late-Breaking Abstracts

LBA 01

Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Localized Prostate Cancer

J.A. Efstathiou,¹ B.Y. Yeap,² J.M. Michalski,³ N. Horick,² A.L. Zietman,¹ J.P. Christodouleas,⁴ S.C. Kamran,¹ R.R. Parikh,⁵ N. Vapiwala,⁴ S.A. Mihalcik,⁶ D.T. Miyamoto,¹ J. Zeng,⁷ H.A. Gay,³ T.M. Pisansky,⁸ M.V. Mishra,⁹ A.J. Wisdom,¹ D.E. Spratt,¹⁰ N.P. Mendenhall,¹¹ E.M. Soffen,¹² and J.E. Bekelman;⁴ ¹Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO, ⁴Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, ⁵Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, ⁶Department of Radiation Oncology, Northwestern Medicine, Feinberg School of Medicine, Chicago, IL, ⁷Department of Radiation Oncology, University of Washington - Fred Hutchinson Cancer Center, Seattle, WA, ⁸Department of Radiation Oncology, Mayo Clinic, Rochester, MN, ⁹Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, ¹⁰Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, ¹¹Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, ¹²Princeton Radiation Oncology, Astera Cancer Care, Jamesburg, NJ

Purpose/Objective(s): Patients with localized prostate cancer have several treatment options including external beam radiotherapy with either photons or protons. Proton beam therapy (PBT) has certain dosimetric advantages with the potential to reduce treatment-associated morbidity and improve oncologic outcomes, but it is generally more resource intensive than intensity modulated radiation therapy (IMRT). To address the hypothesis that PBT results in improved patient-reported outcomes (PROs), PARTIQoL (NCT01617161) was conducted as a multi-center phase 3 randomized trial comparing the two modalities.

Materials/Methods: Patients with intermediate- or low-risk prostate cancer were randomized to PBT or IMRT, without hormonal therapy, stratified for institution, age, rectal spacer use, and fractionation (79.2 Gy/44 fractions vs 70 Gy/28 fractions). Participants were followed longitudinally to assess PROs of bowel, urinary, and sexual function for 60 months (mo) after completion of radiotherapy. Primary endpoint was to compare change from baseline in bowel quality of life (QOL) using the health care software score (range 0-100) at 24 mo. Secondary objectives include comparison of urinary and sexual functions, toxicity, and efficacy endpoints.

Results: Between 06/2012-11/2021, 450 patients from 30 recruiting centers were randomized: PBT (N=226) and IMRT (N=224), of whom 221 and 216 were eligible and started radiation on the respective arms. Median follow-up was 60.3 mo among 424 patients still alive. Median age was 68 yrs (range 46-89), 59% had intermediate-risk disease, 51% received

hypofractionation, 48% used a rectal spacer, and 49% of PBT patients were treated with pencil beam scanning. There was no difference between PBT or IMRT in mean change of health care software bowel score at 24 mo ($p=0.836$), with both arms showing only small, clinically non-meaningful decline from baseline (see Table). Similarly, there was no difference in bowel function at earlier timepoints (3, 6, 9, 12, 18 mo) or later timepoints (36, 48, 60 mo). No differences were observed in other domains (urinary, sexual, hormonal) at any timepoint. There was no difference in progression-free survival (PFS) (93.4% vs 93.7% at 60 mo, HR 1.16 [0.53, 2.57], $p=0.706$). There was no sustained difference in any QOL domain or PFS between arms in subgroups defined by stratification variables.

Conclusion: This prospective randomized clinical trial shows that patients treated with contemporary radiotherapy for localized prostate cancer achieve excellent QOL with highly effective tumor control, without measurable differences between PBT and IMRT. We continue to monitor participants for longer follow-up and secondary endpoints.

LBA 01 – Table 1

Health care software bowel score Mean (Std Dev)	PBT (N=221)	IMRT (N=216)	p-value
Baseline	93.7 (7.8)	93.5 (7.9)	
24 mo	91.8 (11.1)	91.9 (8.6)	
Change	-2.4 (9.7)	-2.2 (9.1)	0.836

Author Disclosure: J.A. Efstathiou: Honoraria; Blue Earth Diagnostics, Boston Scientific, Janssen, Bayer Healthcare, Progenics Pharmaceuticals, Pfizer, Gilead, Myovant, Lantheus, IBA, Angiodynamics, Elekta, Astellas, Genentech. Vice-Chair GU, Bladder lead; NRG Oncology. board member; ROI, ACRO, Massachusetts Prostate Cancer Coalition (MPCC). B.Y. Yeap: None. J.M. Michalski: Grant/research funding; NCI. Travel expenses; Michalski and Associates. Compensation/Payment; Michalski and Associates. Oversee portfolio of NCI NCTN clinical trials in genitourinary cancers; NCI. Treasurer and board of directors; RTOG Foundation. N. Horick: None. A.L. Zietman: None. J.P. Christodouleas: Grant/research funding; Merck, Inc. Stock; Elekta, AB. S.C. Kamran: Employee; Sanofi. Grant/research funding; Prostate Cancer Foundation, NRG Oncology. Honoraria; Varian, DAVA Oncology. Travel expenses; DAVA Oncology, NRG Oncology. American Board of Radiology Radiation Oncology Certifying Exam Genitourinary Committee; American Board of Radiology. Director of Diversity, Equity & Inclusion for the Department. R.R. Parikh: Honoraria; Mevion Medical Systems, MyCareGorithm, LLC. N. Vapiwala: Honoraria; Elsevier Publishing. Uncompensated; NCI - National Cancer Institute. Co-Chair overseeing monthly meetings on research concepts and projects; ECOG-ACRIN. Effective June 2023; ASCO. S.A. Mihalcik: None. D.T. Miyamoto: Grant/research funding; Cardiff Oncology. J. Zeng: Grant/research funding; IBA, AstraZeneca, Gilead. Honoraria; IBA, AstraZeneca. Compensation/Payment; IBA, AstraZeneca. H.A. Gay: Honoraria; BSCI. T.M. Pisansky: Emeritus; Mayo Clinic. M.V. Mishra: Employee; Orthofix. Honoraria; Humanetics. A.J. Wisdom: None. D.E. Spratt: Honoraria; Boston Scientific, Astellas, Janssen, Elekta, Varian, Gammatile, Myovant/Pfizer, Novartis, AstraZeneca, Myovant/Pfizer. N.P. Mendenhall: